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in fact, it is not manifest in the data pre-
sented by Lieske  et al. , 3 possibly because 
the basal values of calciuria in the patients 
studied were relatively low. Moreover, the 
limited intake of lipids (15 % of the total 
calories) gives an increase of the amount 
of free calcium in the bowel. Finally, the 
reduced intake of animal protein trans-
lates into a minor availability of hydroxy-
proline, which, as already mentioned, is 
an important precursor of oxalate. 
 With regard to the apparent failure of 
the probiotic therapy tested by Lieske 
 et al. , 3 one can speculate that the subjects 
examined, having been in any case on a 
low-oxalate diet, were characterized by a 
low intestinal oxalate load and, therefore, 
subsequently reduced substrate for 
microorganisms. In fact, many studies 
that have found probiotic therapy eff ec-
tive in treating hyperoxaluria and, in 
gene ral, calcium nephrolithiasis exam-
ined patients with oxalate values greater 
than those in the current study or patients 
who were given an oral oxalate load. It is 
also possible that the probiotic dose was 
inadequate. 
 Ultimately, in calcium nephrolithiasis 
with hyperoxaluria treatment, along with 
the necessary dietary prescriptions —
 including adequate hydration; reduction 
in salt, proteins, lipids, and simple sugars; 
and correct intake of calcium, fruit, and 
vegetables — therapy with probiotics also 
plays a role, particularly in patients with 
enteric hyperoxaluria and / or high values 
of oxaluria. 
 In the future, dose-fi nding studies will 
be necessary, as well as a careful selection 
of the microorganism strains on the basis 
of metabolic characteristics, vitality, intes-
tinal colonization capacity, and eff ects of 
association with prebiotics (for example, 
inulin), in order to possibly test the effi  -
cacy in other types of nephrolithiasis, such 
as uric acid nephrolithiasis. 
 We look forward to seeing advances 
in technology and an improvement 
of knowledge in order to create, in the 
short term, true  ‘ functional foods ’ 
for nephrolithiasis that are useful in 
the prevention and treatment of this 
common disease. 
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 Potential benefits of alkali 
therapy to prevent GFR loss: 
time for a palatable  ‘ solution ’ 
for the management of CKD 
 Vaibhav  Sahni 1 ,  Robert M.  Rosa 1 and  Daniel  Batlle 1 
 There is increasing evidence that alkali therapy can retard progression of 
chronic kidney disease (CKD). We summarize recent studies and discuss a 
mechanism whereby alkali therapy may neutralize acid production 
associated with typical Western diets, which generate acid. We emphasize 
the rationale for using alkali therapy early in the course of CKD, even in the 
absence of overt metabolic acidosis, and we urge the pharmaceutical 
industry to develop palatable alkali- containing solutions. 
 Kidney International (2010)  78, 1065 – 1067.  doi: 10.1038/ki.2010.364 
 Traditionally, alkali therapy in chronic 
kidney disease (CKD) has been reserved 
for patients with overt metabolic acidosis. 
Th e reasoning has been that the primary 
purpose in treating metabolic acidosis 
associated with CKD is to prevent bone 
disease, improve the nutritional status, 
and prevent muscle wastage. 1 Th ese goals 
are themselves very good reasons to use 
more bicarbonate therapy in the CKD 
population, and the Kidney Disease Out-
comes Quality Initiative (K / DOQI) 
guidelines now have addressed this issue, 
though, in our opinion, not as forcefully 
as would be desirable. 2 In this Commen-
tary, we wish to address recent evidence 
that bicarbonate therapy may help pre-
vent the decline of glomerular fi ltration 
rate (GFR) over time. The question 
we would like to pose is: Should alkali 
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supplementation be used as a part of a 
standard regimen to preserve renal func-
tion in patients with CKD? 
 Th ough large human randomized con-
trolled studies evaluating alkali therapy 
in CKD patients have not yet been done, 
a number of smaller human studies sug-
gest benefi t. 3 – 6 Over the past year, three 
clinical studies have been published. 4 – 6 
De Brito-Ashurst  et al. 4 conducted a ran-
domized, placebo-controlled trial of oral 
sodium bicarbonate supplementation in 
134 adults with advanced CKD (GFR 
15 – 30  ml / min per 1.73  m 2 ) and serum 
bicarbonate concentrations between 16 
and 20  mmol / l. At the end of 2 years of 
follow-up, 22 patients in the control 
group but only four in the bicarbonate 
group progressed to dialysis (6.5 versus 
33 % , respectively). Among the patients 
who did not require initiation of dialysis, 
those in the bicarbonate group were sig-
nifi cantly less likely to experience rapid 
progression defi ned by a loss of GFR of 
more than 3  ml / min per 1.73  m 2 per year 
(9 versus 45 % ). 4 Consistent with these 
fi ndings from England, two studies from 
Wesson ’ s group in the United States 
showed benefi t of alkali-based therapies, in 
the form of either bicarbonate 5 or citrate, 6 
in retarding the rate of progression of 
CKD. In a non-randomized, unblinded 
study, 59 patients with hypertensive 
nephropathy (mean GFR  ~ 33  ml / min) 
and metabolic acidosis (mean total CO 2 
 ~ 20.5  m mol/l ) were allocated to receive 
placebo or sodium citrate (1  mequiv. / kg / d 
in three divided doses). 6 It should be 
noted, however, that this intervention was 
initiated after appropriate control of 
hypertension on regimens that included 
angiotensin-converting enzyme inhi-
bitors. 6 Aft er 2 years of follow-up, the 
GFR was about 5  ml / min higher in the 
alkali-treated group. 6 Urine endothelin-1 
excretion, a surrogate of kidney endothe-
lin production, and  N -acetyl-  - D -glu-
cosaminidase (NAG), a marker of kidney 
tubulointerstitial injury, were also 
improved in the citrate-treated group. 6 In 
a 5-year, prospective, randomized, con-
trolled, blinded study, the eff ect of daily 
oral sodium bicarbonate (0.5  mequiv. / kg) 
versus sodium chloride versus placebo 
was studied in 120 patients (40 in each 
group) with CKD, also due presumably 
to hypertensive nephropathy. 5 In this 
study, patients had early CKD (mean 
GFR  ~ 75  ml / min, estimated with the use 
of plasma cystatin C). GFR at the end of 
the study was signifi cantly higher in the 
bicarbonate-treated group, by about 5  ml /
 min. 5 Th ere was also benefi t in terms of 
albumin excretion and NAG excretion, 
which were both signifi cantly reduced. 5 
Interestingly, in these patients with a 
higher GFR, metabolic acidosis was not 
present. 5 Th us, it appears that bicarbo-
nate therapy may retard the decline in 
GFR in both the presence and the absence 
of overt metabolic acidosis, as well 
as in widely diff erent stages of CKD. 
 What could be the mechanism for 
the beneficial effect of alkali therapy 
on kidney function? As expected, the 
alkali-treated groups had a signifi cant 
reduction in net acid excretion. 5,6 Much 
of the decline in net acid excretion was 
due to a reduction in ammonium excre-
tion. In the rat model of renal ablation, 
bicarbonate treatment attenuates intersti-
tial damage and improves GFR in asso-
ciation with reduced ammonium 
excretion. 7 Increased ammonium in the 
kidney fosters complement activation, 
which leads to tubulointerstitial injury 
( Figure 1 ). Th is observation led to a theory 
of acidosis causing deterioration of kidney 
function, proposed by Nath, Hostetter, 
and Host etter. 7 Th e work of Wesson  et al. 
over the past several years has provided 
additional insights regarding the rela-
tionships between acid excretion, dietary 
protein, intrarenal acid accumulation, 
and CKD progression in experimental 
animals. 8 Activation of endothelin is an 
important part of the story. Dietary pro-
tein increases endothelin production, 
probably by providing an acid load, and 
bicarbonate therapy reduces it and, in the 
process, improves renal injury. 8 Endothelin 
receptor antagonists, moreover, can 
reduce renal injury in the rat renal abla-
tion model, and there are clinical trials 
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 Figure 1  |  Proposed scheme for the effect of increased acid load from high protein intake on 
chronic kidney disease progression and its reversal by early alkali therapy . The development 
of acidosis with normal plasma bicarbonate (eubicarbonatemic acidosis) or with reduced plasma 
bicarbonate will depend on the interplay between the level of kidney function and dietary 
protein intake, which generates an acid load. The administration of alkali early on can suppress 
the enhanced kidney response to excrete acid and thereby prevent the subsequent events that 
lead to progression of chronic kidney disease (CKD). The levels of ammonium (NH 4 
  +   ) and net acid 
excretion  are not increased in absolute terms but require increased work per nephron to maintain 
acid balance. The question marks in the box for kidney acid accumulation and intracellular acidosis 
reflect that more information is needed to support this concept. GFR, glomerular filtration rate. 
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under way in patients with CKD, as 
recently summarized. 9 
 Now Wesson and Simoni 10 (this issue) 
show that in the 2 / 3 nephrectomized rat 
model mimicking early CKD, without 
overt metabolic acidosis, the levels of 
aldosterone and endothelin are increased 
in the kidney, presumably in the renal 
interstitial compartment as well as sys-
temically. Administration of either an 
endothelin or an aldosterone antagonist 
(darusentan or eplerenone, respectively) 
attenuated the loss in GFR at 24 weeks. 
Importantly, when rats were treated with 
dietary alkali (calcium bicarbonate), there 
was no statistically signifi cant loss of GFR 
at 24 weeks, an eff ect larger than that of 
eplerenone, darusentan, or both com-
bined. It was also shown that rats who 
received alkali had endothelin-1 and 
aldosterone levels reduced to the levels of 
controls. 10 Th e better results with alkali 
compared with darusentan and epler-
enone suggest that a mechanism or mech-
anisms in addition to endothelin and 
aldosterone are also involved in the GFR 
decline in the nephrectomy model and its 
prevention by alkali. Could angiotensin II 
also be activated intrarenally and then 
suppressed by alkali therapy in CKD? Th is 
is something that we think should be 
investigated. Another question that comes 
to mind is why the levels of hormones 
such as endothelin and aldosterone are 
elevated intrarenally ( Figure 1 ), 10 as the 
paper suggests. One possibility is that the 
acidic environment could delay the deg-
radation of these peptides. Whatever the 
mechanism, this study suggests that kid-
ney acid accumulation associated with 
increased levels of these hormones leads 
to progression of kidney disease, even 
in early CKD when serum acid – base 
parameters are normal. Th us, it seems as if 
the mere need to excrete more acid to main-
tain overall acid balance, while rats are kept 
on a high-protein diet, prevents acidosis, 
but as a trade-off  there is intrarenal accu-
mulation of acid that promotes injury and 
progression of CKD ( Figure 1 ). 
 Alpern and Sakhaee have proposed that 
eubicarbonatemic acidosis may have long-
term deleterious consequences for bone 
health, namely the development of osteo-
penia and pathological fractures. 11 We 
speculate that the kidney may also suff er 
in the long term from its own eff orts in 
preventing acidosis and maintaining a 
normal acid – base status by excreting acid. 
Th e associated increase in both endothelin 
and aldosterone promotes renal injury by 
pathways that involve ammonium-
dependent and -independent mechanisms 
( Figure 1 ). Independently of extracellular 
pH, a reduction in intracellular pH at the 
kidney level could also be involved in the 
proposed pathogenetic scheme. A prece-
dent already exists for reduced intracel-
lular pH in lymphocytes from rat models 
of hypertension even though extracellular 
pH was not signifi cantly reduced. 12 Inter-
estingly, the reduced intracellular pH was 
associated with increased net acid excre-
tion in the Dahl rat, and this model of 
hypertension is very prone to the develop-
ment of progressive kidney injury. 12 
 Regardless of these speculative mecha-
nisms, the fact remains that alkali-based 
therapies are underutilized in patients 
with CKD. What we want to emphasize is 
that there is some rationale for their use 
early in the course of CKD, even in the 
absence of overt metabolic acidosis as a 
preventive measure ( Figure 1 ). We hope 
that the recent fi ndings outlined above 
will foster more research on the potential 
of alkali-based therapies, the optimal 
dose, and the time of initiation in the 
management of the various stages of CKD. 
It is also important to develop alkali-based 
formulations that are more palatable than 
either sodium bicarbonate or citrate to 
address the serious limits to the compli-
ance of patients taking these solutions. 
Perhaps the recent evidence briefl y sum-
marized in this Commentary will generate 
interest in the pharmaceutical industry 
regarding the development of better-toler-
ated alkali-based formulations. Until these 
are available commercially, the advice of 
the legendary nephrologist Franklin 
Epstein comes to mind: dissolve sodium 
citrate in syrup of wild cherry and patients 
will tolerate it and will be more compli-
ant. 13 We think Dr Epstein would be 
pleased to see an increased use of alkali-
based therapies (in fl avored wild cherry or 
otherwise) as an integral part of the com-
prehensive care of CKD. 
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